Verastem Oncology

November 1, 2019November 11, 2019

Copiktra May Be Treatment Option for Advanced Marginal Zone Lymphoma, Trial Data Show

News

Copiktra (duvelisib), developed by Verastem Oncology, may be an effective and reasonably safe treatment option for people with marginal zone lymphoma who failed to respond to prior therapies including rituximab, Phase 2 data ... Read more

October 29, 2019

Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest

News

Treatment with Copiktra (duvelisib) doubles response rates compared with Arzerra (ofatumumab), and significantly extends the time until disease progression or death in people with chronic lymphocytic leukemia (CLL) or small ... Read more

October 10, 2019

Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment

News

The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, ... Read more

June 27, 2019June 27, 2019

Copiktra Induces Promising Clinical Activity in PTCL Patients, Phase 1 Trials Show

News

Copiktra (duvesilib) shows promising clinical activity in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), inducing responses in 44% to 57% of patients included in Phase 1 trials. The ... Read more

October 16, 2018

Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces

News

Copiktra (duvelisib) monotherapy may be an effective and safe treatment option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to results from a Phase 3 ... Read more

October 1, 2018October 3, 2018

FDA Approves Copiktra Capsules for 2 Lymphoma Types, Verastem Announces

News

The U.S. Food and Drug Administration approved Copiktra (duvelisib) capsules for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a minimum of two prior therapies. ... Read more

September 18, 2018

Verastem Launches Phase 1/2 Trial to Evaluate Duvelisib-Venclexta Combo in CLL/SLL Patients

News

Verastem Oncology has dosed the first patient in its Phase 1/2 trial testing a combination of duvelisib and Venclexta (venetoclax) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who failed ... Read more